Skip to main content

Rick Pearson 2

Rick Pearson in TheStreet.com

Orient Paper: Story Behind 'Fraud' Report

Rick Pearson, who is long the stock, happened to tour the company with the writers of a critical report that hurt the shares, and he questions their research.

China Stocks: Price vs. Fundamentals

Individual company fundamentals are now taking a back seat to overall market sentiment in determining stock prices, creating an opportunity to occasionally pick up value stocks on the cheap.

Duoyuan Printing Sits Pretty in Ugly Market

Despite tremendous profitability and a listing on the New York Stock Exchange, Duoyuan Printing has traded down to where its P/E is only 6.5 times trailing earnings.

How an Uplisting Works

The potential uplisting of Biostar has created some misconceptions about how a stock makes its way to a major exchange.

Finding Uplist Clues: Getting in Before Prices Pop

Rick Pearson is focusing on New Energy Systems and Biostar Pharmaceutical as he sees them uplisting soon.

Biostar: Best Small-Cap Pharma Stock

Biostar has recently applied for a Nasdaq listing and could be a double or triple once it trades on the Nasdaq.

China Energy Stock a Buy, Ignore the Math

New Energy Systems will soon release annual results that contain non-cash charges related to share issuances and acquisitions. There are two reasons I will ignore those charges.

A123 Illustrates Perils of Wall Street Research

Not since the blazing days of the Internet boom have I seen a more deserving candidate for a 'strong sell' recommendation.

Fuqi Fall Highlights Risk in China Small-Caps

There are certain guidelines to be followed when investing in China small-caps.

A Chinese Stock to Watch

China Carbon Graphite looks as if could be a three-bagger if it can get uplisted by Nasdaq and earn $6 million in 2010.